The wise choice for your eyes… since 2007

Cataract Programs

clouding of the eye’s lens

A cataract is a clouding of the normally clear lens of the eye, causing blurred vision, glare and other issues with color perception and night vision. Cataracts are a progressive disease of the eye caused by aging or injury that can lead to impaired vision or if untreated, blindness.

Cataract Standard Program

3 months supply

Standard Program

Cataract Standard Program

$140.00 or $133.00 every 3 months

The Cataract Standard Program includes a 3 month supply of Can-C™ Eye Drops.
4 Packages of Can-C™ Eye Drops

Choose a purchase plan:

  • Free shipping on all U.S. orders!

Guaranteed Safe Checkout

BENEFITS OF THE PROGRAM

  • Same program length as clinical study for initial results.
  • Healthy eyes contain high levels of the natural antioxidant L-Carnosine. Interestingly, the eyes of those suffering from degenerative ocular diseases such as Cataracts were found to be highly deficient in L-Carnosine. Can-C™ Eye Drops help counter oxidative stress on the eyes and provide targeted support for those who suffer from Cataracts.
  • The prime ingredient in Can-C™ is a proprietary form of N-Acetyl-Carnosine (NAC), which acts as both a stabilizer and carrier for L-Carnosine, safely delivering it into the fluid area of the eye surrounding the lens, allowing Carnosine to access the areas it needs to in order to act as a natural and highly effective antioxidant that protects and heals the eye from Cataracts and other ocular disease.
  • Years of research went into identifying the optimal purity factor of N-Acetyl-Carnosine (NAC) to ensure safety as well as optimal results. This purity level is proprietary to our Can-C™ N-Acetyl-Carnosine Eye Drops, so look for the approved Can-C™ hologram on the box of any Can-C™ eye drop product prior to applying to the eyes.

Cataract Advanced Program

6 week supply

Advanced Program

Cataract Advanced Program

$104.95 or $99.70 every 6 weeks

With Nac-C Plus™ for enhanced support

Subscribe & Save

  • Free shipping on all U.S. orders!

Guaranteed Safe Checkout

BENEFITS OF THE PROGRAM

• Same benefits as Standard Program, with accelerated results PLUS:

• Nac-C Plus™ Capsules enhance the effectiveness and duration of Can-C™ Eye Drops’ activity in the eye, thereby speeding up the healing response. In addition, Nac-C Plus™ Capsules reduce oxidation in the eyes and may facilitate a healing response in the eyes of Cataract patients.

• Nac-C Plus™ Capsules work together with Can-C™ Eye Drops to support and speed up the healing process by keeping the lens of the eye safe from degradation, delivering essential nutrients, enhancing DNA repair, and reducing oxidative stress that could otherwise inhibit the natural healing process. These capsules include natural vitamins, minerals, antioxidants, and amino acids that have been clinically proven to help improve eye health and fight common eye disease like Cataracts.

• Ingredients in Nac-C Plus™ Capsules like N-Acetyl-Cysteine, L-Histidine, and L-Carnosine have been show to work synergistically to improve vision by increasing glutathione levels and acting as antioxidants to spare the lens of the eye from oxidative stress, keeping it flexible and clear. Vitamin E and Zinc can also decrease risk of Cataracts and other age-related eye disease.

A higher (loading) dose of Can-C™ Eye Drops is recommended in the first few months of use to quickly re-establish optimal N-Acetyl-Carnosine (NAC) levels in the eyes; two drops applied in the morning to each eye (4 drops total) and two drops in the evening to each eye (4 drops total). The quicker these levels can be elevated in your eyes the sooner you will begin to see visual improvements. This initial (loading dosing period) lasts anywhere from 3 to 6 months depending upon the severity of your eye condition.

Once you begin to see notable improvements in brightness and clarity you may be confident that you have effectively re-established optimal NAC levels in your eyes, but the improvements don’t stop there. The good news is that once the NAC levels have been re-established to optimal levels in the eyes it is very easy to keep them there at half the cost. After three to six months of consistent use, only half the recommended Can-C dose is needed to effectively maintain these new levels, and the vision improvements will continue.

While many report visual improvements in as little as three months’ time, generally the most dramatic improvements will be reached between six and twelve months of consistent use. Once optimal results have been achieved, the maintenance dose of only one to two drops daily will prevent the return of the Cataracts and continue to support and improve the health of your eyes.

The benefits of Can-C™ are long-lasting, however if the drops are discontinued, the same deficiency that allowed the ocular condition to form in the first place will likely return again. Fortunately, by simply using a minimal amount of the product consistently, the good results can be maintained at less than half the initial cost.

Can-C™ eye drops initial loading dose: two drops applied in the morning to each eye (4 drops total) and two drops in the evening to each eye (4 drops total).

Can-C™ eye drops maintenance dose (general eye health support and prevention): After 3 to 6 months of use you will only need to use 1-2 drops of Can-C™ in each eye daily, with a one week pause from use every two months. The product will last a very long time at this level of usage.

Advanced Program Protocol
Nac-C Plus™ Capsules dose: take 2 capsules daily Nac-C Plus™ Capsules. When used in conjunction with Can-C™ eye drops, Nac-C Plus capsules increase the length of time that Can-C™ eye drops stay active in the eye by inhibiting the breakdown of the L-carnosine that has been topically administered through the drops. This sustained effect significantly enhances free radical protection and decreases the oxidative environment within the eye, allowing for a faster healing response.

Independent clinical results are based on consistent daily use.

Previously, cataract formation resulting in the need for cataract surgery was believed to be an inevitable part of the aging process. Current Research has revealed that the topical application of specific nutrients to the eyes can prevent and even reverse the progression of cataract severity for thousands of aging individuals.  In clinical trials Can-C eye drops applied daily were shown to reverse protein aggregation (oxidation) and inflammation in the majority of subjects thereby allowing the eyes’ natural repair mechanisms to keep the ocular lens clear.

What are Cataracts?

A cataract is a clouding or loss of transparency in the lens of the eye that affects your vision. This cloudiness occurs when the crystallin proteins in your eye break down and begin clumping together due to the loss of essential ocular amino acids. If left untreated, progression of cataracts can lead to severe vision loss requiring cataract surgery. Unfortunately for millions of people, Cataracts are still the leading cause of blindness in humans.

Is there an alternative to Cataract surgery?

Cataract removal surgery is not always a treatment option due to the fear of eye surgery risks and the potential for adverse events in any surgical procedure. Additionally, even with insurance, access to surgery is an issue for those on fixed incomes. Sadly, many people are unaware of the recent advancements in non-surgical treatment options to slow cataract progression and ultimately reverse it’s formation.

What are symptoms of Cataracts?

Symptoms include clouded, blurred or dim vision, double vision in a single eye, sensitivity to light and glare, poor night vision or need for brighter light when reading, faded color vision, and vision loss. If your eyewear prescription needs to change frequently, it may also be a sign of advancing age-related cataract.

What causes Cataracts?

Cataracts are largely caused by inflammatory health conditions and aging human lens cells. According to the National Eye Institute, by age 65 about 25% of the population develop cataracts and per the American Academy of Ophthalmology, by the age of 75,  half of Americans have developed them and the associated impaired vision.

How effective are eye drops for Cataracts?

Ground breaking research by molecular biologist, Dr. Mark Babizhayev demonstrates that the compound N-acetylcarnosine (NAC) may be used as an eye drop solution to reverse, reduce or slow cataract progression for positive patient outcome. Our patented formula eye drop containing NAC, Can-C™,  is the result of Dr. Babizhayev’s extensive research and Wise Choice Medicine’s founding relationship with Innovative Vision Products and Profound products.

What about dogs with cataracts?

In the animal studies, university researchers found Can-C eye drops to be equally effective in generating reversal of lens opacity in dogs eyes, restoring lens transparency and visual acuity.  Notably they found that cataracts in canine eyes showed a faster response time to the eye drop applications than human eyes due to chemical distinctions of the canine eye.

How do Can-C™eye drops work?

Clinical trials demonstrate that Can-C™ N-acetylcarnosine (NAC) eye drops are a game changer. They help the aging eye to recover by improving its clarity, glare sensitivity, color perception and overall vision when used as part of an eye care routine. They improve eye health and visual function via several mechanisms1:

  1. NAC metabolizes into the protein L-carnosine when it penetrates the cornea, preventing inactivation of antioxidants in lens cells by free-radicals.
  2. L-carnosine prevents autooxidation of glycation reactions to the lens proteins by competing for the glycating agent, protecting the crystalline lens proteins against modification.
  3. L-carnosine is a universal antioxidant with scavenging activity towards lipid hydroperoxides, aldehydes and oxygen radicals, preventing oxidative stress and damage to the lens.
  4. L-carnosine activates proteasome activity in the lens to reverse aggregation in cataracts, restoring clarity to the lens.

REFERENCE: 

1. Mark A Babizhayev, Philip Micans. N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population. Clin Interv Aging. 2009;4:31-50. Epub 2009 May 14.Stuart P Richer. 

CLINICAL STUDY

In study 90.0% of the eyes treated with N-acetylcarnosine, 1% sol (NAC) showed a gradual improvement in b/c VA to 7-100%

Study: N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts.
Publication: PMID: 11390029 DOI: 10.1016/s0196-9781(01)00407-7
Date published: January 28, 2022
Authors: M A Babizhayev, A I Deyev, V N Yermakova, Y A Semiletov, N G Davydova, N I Kurysheva, A V Zhukotskii, I M Goldman
Summary: A study was designed to document and quantify the changes in lens clarity over 6 and 24 months in 2 groups of 49 volunteers (76 eyes) with an average age of 65.3 +/- 7.0 enrolled at the time of diagnosis of senile cataracts of minimal to advanced opacification. The patients received N-acetylcarnosine, 1% sol (NAC) (26 patients, 41 eyes = Group II), placebo composition (13 patients, 21 eyes) topically (two drops, twice daily) to the conjunctival sac, or were untreated (10 patients, 14 eyes); the placebo and untreated groups were combined into the control (reference) Group I. Patients were evaluated upon entry, at 2-month (Trial 1) and 6-month (Trial 2)-intervals for best corrected visual acuity (b/c VA), by ophthalmoscopy and the original techniques of glare test (for Trial 1), stereocinematographic slit-image and retro-illumination photography with subsequent scanning of the lens. The computerized interactive digital analysis of obtained images displayed the light scattering/absorbing centers of the lens into 2-D and 3-D scales. The intra-reader reproducibility of measuring techniques for cataractous changes was good, with the overall average of correlation coefficients for the image analytical data 0.830 and the glare test readings 0.998. Compared with the baseline examination, over 6 months 41.5% of the eyes treated with NAC presented a significant improvement of the gross transmissivity degree of lenses computed from the images, 90.0% of the eyes showed a gradual improvement in b/c VA to 7-100% and 88.9% of the eyes ranged a 27-100% improvement in glare sensitivity. Topographic studies demonstrated less density and corresponding areas of opacification in posterior subcapsular and cortical morphological regions of the lens consistent with VA up to 0.3. The total study period over 24 months revealed that the beneficial effect of NAC is sustainable. No cases resulted in a worsening of VA and image analytical readings of lenses in the NAC-treated group of patients. In most of the patients drug tolerance was good. Group I of patients demonstrated the variability in the densitometric readings of the lens cloudings, negative advance in glare sensitivity over 6 months and gradual deterioration of VA and gross transmissivity of lenses over 24 months compared with the baseline and 6-month follow-up examinations. Statistical analysis revealed the significant differences over 6 and 24 months in cumulative positive changes of overall characteristics of cataracts in the NAC-treated Group II from the control Group I. The N-acetylated form of natural dipeptide L-carnosine appears to be suitable and physiologically acceptable for nonsurgical treatment for senile cataracts.

CLINICAL STUDY

In clinical test NAC-treated eyes had statistically significant difference in VA, glare sensitivity compared to control at 4-months

Study: Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops.
Publication: PMID: 15588519 DOI: 10.1089/rej.2004.7.186
Date published: January 28, 2006
Authors: Mark A Babizhayev
Summary: The purpose of this study was to examine using the original halometer glare test of the type of visual impairment mediated by the increased glare sensitivity (halos) and associated with poorer visual function in both the better and worse eyes of older adult drivers and older drivers with cataract. The clinically validated original formula of 1% N-acetylcarnosine (NAC) lubricant eye drops were applied topically to the eyes of older drivers to reduce glare disability and improve distance acuities for driving. This was a randomized, double-blind, placebo-controlled study. The examined subjects consisted of 65 older adults, with cataract in one or both eyes, and 72 adult drivers who did not have cataract in either eye. In the control group, comparison with baseline values showed some variability of data in gradual worsening of glare sensitivity at red and green targets and minimal VA changes over 4 months. In the NAC-treated group, 4-month follow-up generally showed an improvement in VA and a significant improvement in glare sensitivity at red and green targets was documented in worse and better eyes using a critical cut point halometer score for driving. The NAC-treated eyes had statistically significant difference in VA, glare sensitivity compared with the control group ( p < 0.001) at 4-month timepoint of treatment, as supported by the overall t-test results of the ratio of the follow-up data to the baseline values. Tolerability of NAC eyedrops was good in almost all patients, with no reports of ocular or systemic adverse effects. The results of this study provide a substantial basis for further evaluation of NAC in the treatment and prevention of vision impairment in the older population of drivers for legal driving. The developed ophthalmic drug NAC formula showed potential for the non-surgical treatment of age-related cataracts.